Can a cholesterol drug tame inflammation in diabetes? small study investigates
NCT ID NCT03829046
First seen May 01, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This completed Phase 4 trial looked at how evolocumab (Repatha), a cholesterol-lowering drug, affects markers of inflammation and blood clotting in 41 people with type 2 diabetes and heart disease. Participants received either evolocumab or a placebo injection every 4 weeks for 12 weeks. The goal was to understand the drug's short-term effects on these biological markers to inform future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROVASCULAR DYSFUNCTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
St. Michael's - University of Toronto
Toronto, Ontario, M5B1W8, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evolocumab (Repatha)
What this could lead to
If successful, this could help design a larger trial to see if evolocumab improves blood vessel function in people with type 2 diabetes.
What could go wrong
This was a small, early-phase study focused on biological markers, not on patient outcomes. It may not lead to a proven treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.